Transcept management is scheduled to present a general business overview at:
Wedbush Securities Life Sciences Best Ideas Conference | |
New York, NY | |
August 3, 2010 at 1:00 p.m. EDT | |
Collins Stewart Health Care Event | |
New York, NY | |
August 11, 2010 | |
A live audio webcast and replay of the presentation at Wedbush Securities conference will be available at http://www.wsw.com/webcast/wedbush13/transcept/ and on the Transcept Investor webpage at www.transcept.com. There will be no formal presentation and no webcast from the Collins Stewart conference.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.
Contact: | |
Transcept Pharmaceuticals, Inc. | |
Greg Mann | |
Director, Corporate Communications | |
(510) 215-3567 | |
SOURCE Transcept Pharmaceuticals, Inc.
